Data from phase I and II studies of advanced NSCLC have suggested encouraging antitumor activity with the combination of an HDAC inhibitor and either platinum-based doublet chemotherapy or an EGFR inhibitor (20, 21). This evidence concerns the gene EGFR and non-small cell lung carcinoma.